To address these multiple issues, we opted to investigate revascularization in the cornea, one of the first tissues used to study angiogenesis [42–45] and where anti-VEGF drugs originally developed for tumor treatment are used clinically [4, 5]. This evidence concerns the gene VEGFA and neoplasm.